Kuros Biosurgery AG Announces Grant Of United States Patent For Synthetic Biomaterials
Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The company’s product candidates are based on one of two different matrix technology platforms; fibrin or synthetic biomaterial matrices. Several product candidates based on synthetic biomaterials are in preclinical development for various trauma, wound and spine indications.
Mr. Didier Cowling, Chief Executive Officer at Kuros commented: “Obtaining this US patent is an important strategic step for Kuros towards ensuring broad protection for product candidates based on its synthetic biomaterial technologies. We are confident that we will receive additional patent grants that will further strengthen our IP position around what is a key technology platform for Kuros. “
The patent is the first in a series of related applications, which has been allowed in the US. Corresponding applications are pending in other important markets including Europe. The patent covers biomaterials which are formed from at least two synthetic precursor components (by a broadly applicable reaction mechanism). The biomaterials can be administered as liquids, foams or gels and solidify in situ at the site of application in the body. These biomaterials can also be designed to contain other components such as bioactive molecules and inert filling materials, allowing their use in a wide range of therapeutic applications.
About Kuros
www.kuros.ch
Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combinations for trauma, wound and spinal indications.
Kuros’ combination products are designed to mimic the body’s natural healing process. The products consist of fusion proteins of naturally occurring bioactive factors, covalently incorporated into fibrin or synthetic matrices. The incorporation of the biologically active molecules into the injectable matrices aims to maximize their activity by retention at the site of action. Kuros products are designed to combine ease of application with localized delivery. Kuros has a number of methodologies to achieve the desired retention and release profiles of the biologically active molecules.
Kuros’ has a diverse pipeline of product candidates with its most advanced products being in trauma and wound care. Since its creation, Kuros has received over $90 million in funding. The company is located in Zurich, Switzerland.